Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kardigan, Inc.KARD · Entity 4569 | Chief Financial Officer | June 17, 2026 | June 22, 2026 |
| LianBioLIAN · Entity 9881 | Chief Business Officer | March 29, 2023 | March 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kardigan, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,640 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 79,640 · Balance 79,640 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.
LianBio
Report date March 29, 2023 · Filed March 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 224,005 |
Reported balance
After 2023-03-29 transaction · row 1
1 source rowRow 1 · 2023-03-29 · Grant · Acquired 224,005 · Balance 224,005 F1: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 23:20 UTC | Kardigan, Inc. KARD · Entity 4569 | GrantCommon Stock | 79,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-277924 · ownership.xml · nonDerivative · entry 1 Jahn Brianne · CIK 0001885012 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,640 F1 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:21 UTC | LianBio LIAN · Entity 9881 | GrantOrdinary Shares | 224,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001831283-23-000054 · wf-form4_168029408142979.xml · nonDerivative · entry 1 Jahn Brianne · CIK 0001885012 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,005 F1 · shares: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:11 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 318,995 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001831283-23-000017 · wf-form4_167459467623989.xml · derivative · entry 1 Jahn Brianne · CIK 0001885012 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,995 Underlying: Ordinary Shares · 318,995 shares Expires 2033-01-20 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| October 31, 2021 Filed Nov 1, 2021 23:23 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 330,942 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042216 · doc4.xml · derivative · entry 1 Jahn Brianne · CIK 0001885012 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,722 Underlying: Ordinary Shares · 330,942 shares Expires 2031-10-31 F1 · derivative.exercise_date: 1/4 of the shares underlying the option will vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.